Vaxcyte(PCVX) Drops 7.95% Amid Vaccine Trial Uncertainty

Vaxcyte(PCVX) shares rose by 1.99% today, marking a significant intraday decline of 7.95% and reaching its lowest level since October 2022.

Vaxcyte's stock price has been influenced by several key factors. The company's Phase II IPD vaccine trial showed promising results, but investors are cautious as they await data from another vaccine candidate before it can proceed to Phase III trials. This uncertainty has contributed to the stock's recent decline.

Adding to the negative sentiment, an analyst at Leerink Partners recently adjusted the target price for Vaxcyte from $153 to $65. This significant reduction in the target price has likely weighed on investor confidence, leading to a sell-off in the stock.

Additionally, the financial results for the fourth quarter and the full year of 2024, released on February 25, 2025, may have also played a role in influencing the stock's performance. While specific details of the financial results are not provided, the market's reaction suggests that the results may not have met investor expectations.